Urologic applications of botulinum toxin therapy for voiding dysfunction

Current Urology Reports

Volumn 5, Issue 5, 2004, Pages 381-388

  Rackley, Raymond ^a   Abdelmalak, Joseph ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Botulinum Toxin; Botulinum Toxin Type; Cervical Dystonia; Dysport; Interstitial Cystitis

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN;

EQUIPMENT DESIGN; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MICTURITION DISORDER; REVIEW; SYRINGE; URETHRA; URINE INCONTINENCE; URINE RETENTION;

ADMINISTRATION, INTRAVESICAL; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; SYRINGES; URETHRA; URINARY INCONTINENCE; URINARY RETENTION; URINATION DISORDERS;

EID: 16644401406     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0088-5     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention: Botulism in the United States, 1899–1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta: Centers for Disease Control and Prevention; 1998.
2. Gill MD: Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982, 46:86–94.
3. Foran PG, Mohammed N, Lisk GO, et al.: Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long-lasting type A. J Biol Chem 2003, 278:1363–1371. DOI: 10.1074/jbc.M209821200
4. Aoki KR, Guyer B: Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001, 8(suppl 5):21–29. DOI: 10.1046/j.1468-1331.2001.00035.x
5. de Paiva A, Meunier FA, Molgo J, et al.: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999, 96:3200–3205. DOI: 10.1073/pnas.96.6.3200
6. Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400–404.
7. Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 1996, 19:488–496. DOI: 10.1002/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8
8. Moreno-Lopez B: Discharge properties of extraocular muscle motoneurons in the alert cat following the peripheral injection of botulinum neurotoxin type A. Mov Disord 1995, 10:386.
9. Priori A, Berardelli A, Mercuri B, Manfredi M: Physiological effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. Brain 1995, 118:801–807. DOI: 10.1093/brain/118.3.801
10. Aoki R: Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology 2003, 60(suppl 1):A212-A213.
11. Botox Package Insert. Irvine, CA: Allergan, Inc.
12. Leippold T, Reitz A, Schurch B: Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003, 44:165–174. Excellent clinical review of the urologic applications of botulinum toxin therapies. DOI: 10.1016/S0302-2838(03)00250-1
13. Smith CP, Chancellor MB: Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004, 2128–2137. The authors provide a basic science and clinical review of the urologic applications of botulinum toxin therapies.
14. Del Popolo G, Li MV, Panariello G, et al.: English botulinum toxin A in the treatment of neurogenic detrusor overactivity. Neurourol Urodyn 2003, 22:498–499.
15. Wyndaele JJ, Van Dromme SA: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002, 40:599–600. DOI: 10.1038/sj.sc.3101318
16. Dykstra DD, Sidi AA: Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990, 71:24–26. A double-blind, placebo-controlled trial with crossover limited to five patients with a 4-week follow-up.
17. BOTOX (Botulinum toxin type A, purified neurotoxin complex) product information. http//www.botox.com/ prescribing_info.html, 2000.
18. Data on file: A Randomized, Multicenter, Double-blind, Placebocontrolled Study of Intramuscular BOTOX) Botulinum Toxin Type A) Purified Neurotoxin Complex (original 79–11 BOTOX) for the Treatment of Cervical Dystonia. Irvine, CA: Allergan, Inc.; 1998.
19. Jankovic J, Vuong KD, Ahsan J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186–1188.
20. Stohrer M, Schurch B, Kramer G, et al.: Botulinum toxin A in the treatment of detrusor hyper-reflexia in spinal cord injured patients: A new alternative to medical and surgical procedures? Neurourol Urodyn 1999, 18:401. DOI: 10.1002/(SICI)1520-6777(1999)18:2<139::AID-NAU9>3.0.CO;2-U
21. Schurch B, Stohrer M, Kramer G, et al.: Botulinum A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692–697. DOI: 10.1016/S0022-5347(05)67283-7
22. Taqi D, Gunyea I, Bhakta B, et al.: Botulinum toxin type A (Botox) in the treatment of refractory myofascial cervicothoracic pain: a prospective trial. Pain Med 2002, 3:173–174.
23. Smuts JA, Barnard PW: Botulinum toxin type A in the treatment of headache syndromes: a clinical report of 79 patients. Cephalgia 2000, 20:332. DOI: 10.1046/j.1468-2982.2000.020004332.x
24. Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(suppl 1):S9-S15. DOI: 10.1046/j.1526-4610.43.7s.3.x
25. Klein AW: The therapeutic potential of botulinum toxin. Dermatol Surg 2004, 30:452–455. DOI: 10.1111/j.1524-4725.2004.30118.x
26. Welch M, Purkiss J, Foster K: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245–258. DOI: 10.1016/S0041-0101(99)00153-1
27. Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125–133. DOI: 10.1016/j.pain.2003.10.008
28. Zermann D, Ishigooka M, Schubert J, Schmidt RA: Perisphincteric injection of botulinum toxin type A: a treatment option for patients with chronic pelvic pain? Eur Urol 2000, 38:393–399. DOI: 10.1159/000020314
29. Jarvis SK, Abbott JA, Lenart MB, et al.: Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 2004, 44:46–50. DOI: 10.1111/j.1479-828X.2004.00163.x
30. Phelan MW, Franks M, Somogyi GT, et al.: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001, 165:1107–1110. DOI: 10.1016/S0022-5347(05)66438-5
31. Kuo HC: Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003, 61:550–554. DOI: 10.1016/S0090-4295(02)02541-4
32. de Seze M, Petit H, Gallien P, et al.: Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind, lidocainecontrolled study of 13 patients with spinal cord disease. Eur Urol 2002, 42:56–62. A double-blind, lidocaine-controlled study evaluating the efficacy of Botox versus lidocaine in 13 patients with detrusor sphincter dyssynergia secondary to spinal cord disease. One transperineal injection of Botox into the external urethral sphincter was found to be superior to lidocaine injection as evidenced by decreased postvoid residual and maximal urethral pressure and increased patient satisfaction scores. DOI: 10.1016/S0302-2838(02)00209-9
33. Dykstra DD, Sidi AA, Scott AB, et al.: Effects of botulinum-A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139:919–922.
34. Doggweiler R, Zermann D, Ishigooka M, et al.: Botox-induced prostatic involution. Prostate 1998, 37:44–50. DOI: 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8
35. Maria G, Brisinda G, Civello IM, et al.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259–265. DOI: 10.1016/S0090-4295(03)00477-1